Lantheus LNTH Stock
Lantheus Price Chart
Lantheus LNTH Financial and Trading Overview
Lantheus stock price | 90.92 USD |
Previous Close | 86.2 USD |
Open | 86.36 USD |
Bid | 0 USD x 1200 |
Ask | 0 USD x 1200 |
Day's Range | 85.65 - 90.34 USD |
52 Week Range | 47.46 - 100.85 USD |
Volume | 1.05M USD |
Avg. Volume | 1.03M USD |
Market Cap | 6.16B USD |
Beta (5Y Monthly) | 0.677464 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 4.36 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 122.38 USD |
LNTH Valuation Measures
Enterprise Value | 6.01B USD |
Trailing P/E | N/A |
Forward P/E | 14.627036 |
PEG Ratio (5 yr expected) | 0.41 |
Price/Sales (ttm) | 5.9939156 |
Price/Book (mrq) | 13.766093 |
Enterprise Value/Revenue | 5.848 |
Enterprise Value/EBITDA | 40.229 |
Trading Information
Lantheus Stock Price History
Beta (5Y Monthly) | 0.677464 |
52-Week Change | 47.90% |
S&P500 52-Week Change | 20.43% |
52 Week High | 100.85 USD |
52 Week Low | 47.46 USD |
50-Day Moving Average | 90.37 USD |
200-Day Moving Average | 71.71 USD |
LNTH Share Statistics
Avg. Volume (3 month) | 1.03M USD |
Avg. Daily Volume (10-Days) | 1.16M USD |
Shares Outstanding | 68.33M |
Float | 66.85M |
Short Ratio | 3.34 |
% Held by Insiders | 2.80% |
% Held by Institutions | 101.29% |
Shares Short | 3.68M |
Short % of Float | 7.08% |
Short % of Shares Outstanding | 5.37% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -1.72% |
Operating Margin (ttm) | 9.59% |
Gross Margin | 62.91% |
EBITDA Margin | 14.53% |
Management Effectiveness
Return on Assets (ttm) | 5.39% |
Return on Equity (ttm) | -3.68% |
Income Statement
Revenue (ttm) | 1.03B USD |
Revenue Per Share (ttm) | 15.01 USD |
Quarterly Revenue Growth (yoy) | 44.00% |
Gross Profit (ttm) | 581.7M USD |
EBITDA | 149.28M USD |
Net Income Avi to Common (ttm) | -17702000 USD |
Diluted EPS (ttm) | -0.26 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 470.86M USD |
Total Cash Per Share (mrq) | 6.89 USD |
Total Debt (mrq) | 586.05M USD |
Total Debt/Equity (mrq) | 131.54 USD |
Current Ratio (mrq) | 2.798 |
Book Value Per Share (mrq) | 6.524 |
Cash Flow Statement
Operating Cash Flow (ttm) | 380.02M USD |
Levered Free Cash Flow (ttm) | -151120128 USD |
Profile of Lantheus
Country | United States |
State | MA |
City | Bedford |
Address | 201 Burlington Road |
ZIP | 01730 |
Phone | 978 671 8001 |
Website | https://www.lantheus.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 698 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.
Q&A For Lantheus Stock
What is a current LNTH stock price?
Lantheus LNTH stock price today per share is 90.92 USD.
How to purchase Lantheus stock?
You can buy LNTH shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Lantheus?
The stock symbol or ticker of Lantheus is LNTH.
Which industry does the Lantheus company belong to?
The Lantheus industry is Drug Manufacturers-Specialty & Generic.
How many shares does Lantheus have in circulation?
The max supply of Lantheus shares is 68.61M.
What is Lantheus Price to Earnings Ratio (PE Ratio)?
Lantheus PE Ratio is 20.85321000 now.
What was Lantheus earnings per share over the trailing 12 months (TTM)?
Lantheus EPS is 4.36 USD over the trailing 12 months.
Which sector does the Lantheus company belong to?
The Lantheus sector is Healthcare.
Lantheus LNTH included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Composite Total Return I XCMP | 19079.55 USD — |
-5.82
|
— — | 19064.73 USD — | 19740.96 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2500.59 USD — |
-5.81
|
— — | 2469.29 USD — | 2585.45 USD — | — - | — — |
NASDAQ Global Market Composite NQGM | 1647.83 USD — |
-5.17
|
— — | 1610.28 USD — | 1681.06 USD — | — - | — — |
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD | 2100.38 AUD 1390.15 USD |
<0.01
|
— — | 2100.38 AUD 1390.15 USD | 2100.38 AUD 1390.15 USD | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}